Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07318558 · ClinicalTrials.gov registry record · Phase 3

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

A Phase 3 study of Ovarian Cancer and Ovarian Neoplasms, sponsored by Merck Sharp & Dohme.

Recruiting
Registry status
Phase 3
Development phase
900
Enrollment target
9
Study locations

NCT07318558: Recruiting Phase 3 study of Ovarian Cancer and Ovarian Neoplasms, sponsored by Merck Sharp & Dohme.

NCT07318558 is a Phase 3 study of Ovarian Cancer and Ovarian Neoplasms that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 900 participants, above the 726-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (24% higher). The trial reports 9 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07318558, a Phase 3 study of Ovarian Cancer and Ovarian Neoplasms, is actively recruiting participants, sponsored by Merck Sharp & Dohme.

RECRUITING
Registry status
Phase 3
Development phase
900 participants
Enrollment target
9
Study locations

Study Summary

Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. * Observation, which is watching to see if cancer grows or worsens The study medicine, sacituzumab tirumotecan (also called sac-TMT), is a targeted therapy. The goal of this study is to learn if people who receive sac-TMT maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care.

Primary Outcome

PFS is defined as the time from randomization to the first documented progressive disease (PD) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 by blinded independent central review (BICR) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions is

Conditions Studied

Ovarian Cancer Ovarian Neoplasms

Interventions

  • DRUG Bevacizumab
  • DRUG Rescue Medications
  • DRUG Sacituzumab tirumotecan

Study Locations (9)

Other

  • Rambam Health Care Campus ( Site 1422) - Haifa
  • Niigata Cancer Center Hospital ( Site 1608) - Niigata
  • Seoul National University Hospital ( Site 2301) - Seoul
  • Asan Medical Center ( Site 2305) - Seoul
  • Linkou Chang Gung Memorial Hospital ( Site 2605) - Taoyuan District

Florida

  • Mount Sinai Cancer Center ( Site 0029) - Miami Beach

Iwate

  • Iwate Medical University Hospital ( Site 1610) - Shiwa-gun

Tokyo

  • Cancer Institute Hospital of JFCR ( Site 1614) - Koto

Seoul

  • Severance Hospital ( Site 2302) - Seodaemun-Gu

Trial Details

FieldValue
Enrollment Target 900 participants
Start Date 2026-02-16
Est. Completion 2033-02-25
Phase Phase 3
Merck Sharp & Dohme

558 total trials

What NCT07318558 shows while recruiting

NCT07318558 is an interventional study that assigns participants to a tested intervention. The registered 900 participants enrollment target is mid-sized for trials with a published cap, above the 726-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (24% higher).

The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.

NCT07318558 lists 9 locations in 5 states (Other, Florida, Iwate).

Frequently Asked Questions

What is clinical trial NCT07318558 about?

NCT07318558 is a clinical study titled "A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)". Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is us...

What is the current status of trial NCT07318558?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 900 participants. The study started on 2026-02-16. Estimated completion is 2033-02-25.

What conditions does trial NCT07318558 study?

This clinical trial studies the following conditions: Ovarian Cancer, Ovarian Neoplasms.

What interventions are being tested in trial NCT07318558?

The interventions under investigation include: Bevacizumab (DRUG), Rescue Medications (DRUG), Sacituzumab tirumotecan (DRUG).

Who is sponsoring clinical trial NCT07318558?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07318558 being conducted?

This trial has 9 study locations across Florida, Iwate, Tokyo, Seoul. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07318558's enrollment target sits among peer trials

900 29th of 322 higher than 294 of 322 other Ovarian Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02352116 · 900 participants · NA

    Evaluation of Post-PACU Pain Management in Pediatric Surgery

  • NCT02414347 · 900 participants

    F 18 T807 Tau PET Imaging of Alzheimer's Disease

  • NCT02670408 · 900 participants

    Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation

  • NCT02960022 · 900 participants · Phase 2

    A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07318558

Source: ClinicalTrials.gov NCT07318558, the US trial registry maintained by the National Library of Medicine. NCT07318558 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.